Oral Ulcer Clinical Trial
Official title:
Evaluation of the Effect of Probiotic Lozenges in the Treatment of Recurrent Aphthous Stomatitis: a Randomized, Controlled Clinical Trial
The application of host-modulating bacteria for therapeutic purposes is one of the strongest emerging fields. Probiotics are live microorganisms, which, when administered in an adequate amount, confer a health benefit on the host The study aimed to explore the effectiveness of probiotics in the treatment of the common ulcerative condition; minor recurrent aphthous stomatitis (RAS). We included sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS . Both groups were divided into two subgroups, AI and BI (test subgroups ) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
The study aimed to explore the effectiveness of probiotics in the treatment of minor recurrent aphthous stomatitis (RAS). We performed a randomized, controlled clinical study. Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups. Compared to baseline, an improvement was evident for all subgroups. However, for effectiveness in pain reduction, a statistically significant difference in favor of AI was observed for all evaluation periods when compared to control subgroup. Regarding effectiveness in ulcer size reduction, a statistically significant difference in favor of BI was observed at day 5 when compared to control subgroup. No significant difference was observed in the effectiveness index between subgroups AI and BI (test subgroups) except in effectiveness in pain reduction at day 3. The outbreak frequency decreased significantly in subgroup BI. We concluded that topical application of probiotics decreased pain intensity and accelerate RAS healing. The effectiveness in pain reduction is more evident in adult patients while acceleration of healing is more evident in children. Probiotics could be a well-tolerated, topical therapeutic agent in the treatment of minor RAS ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03239834 -
Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making
|
||
| Not yet recruiting |
NCT04989049 -
Therapeutic Effect of Folic Acid in Healing of Oral Ulcers
|
Early Phase 1 | |
| Completed |
NCT06379438 -
Treatment of Aphtous Ulcers With Photodynamic Therapy
|
N/A | |
| Withdrawn |
NCT02769494 -
The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer
|
Phase 3 | |
| Completed |
NCT05413096 -
Combination of Diclofenac Potassium and Propolis in the Therapy of Oral Aphthosis
|
Early Phase 1 | |
| Completed |
NCT03633292 -
Aloe Vera and Chlorhexidine Against Traumatic Oral Ulcers
|
Phase 4 | |
| Completed |
NCT00333749 -
The Effectiveness of Pasteurized Goat Milk in the Treatment of Childhood Oral Ulcer Diseases
|
Phase 1 | |
| Recruiting |
NCT04710888 -
Basil Extract (Ocimum Basilicum) in the Management of Recurrent Aphthous Stomatitis
|
Phase 2 | |
| Completed |
NCT05147376 -
Effectiveness of a Curcumin Mouthwash in Preventing Traumatic Ulcers in Patients With Fixed Orthodontic Appliances
|
Early Phase 1 | |
| Completed |
NCT03167632 -
Oral Ulcer Prevalence: Hospital-based Cross-sectional Study
|
N/A | |
| Enrolling by invitation |
NCT05288478 -
Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.
|
Phase 2 | |
| Recruiting |
NCT05449548 -
Lenalidomide in the Treatment of Mucosal Behçet's Syndrome
|
N/A | |
| Completed |
NCT05032248 -
Uses of Tacrolimus in Behcet Disease
|
N/A |